|
ACW CEO presentation on emerging oral Alzheimers therapies
|
21 June 2023 at 9:20am
|
|
ACW CEO & CMO present at BIO International Convention
|
5 June 2023 at 9:35am
|
|
ACW AD trial amendment and Clinical Science Forum slides
|
24 May 2023 at 8:45am
|
|
Quarterly Activity Report & Appendix 4C
|
24 April 2023 at 9:25am
|
|
Actinogen CMO presents at ADPD 2023 conference
|
31 March 2023 at 8:35am
|
|
Application for quotation of securities - ACW
|
20 March 2023 at 11:20am
|
|
Appendix 3X - Dr Nicki Vasquez
|
1 March 2023 at 9:55am
|
|
ACW appoints Dr Nicki Vasquez as a Non-Executive Director
|
1 March 2023 at 9:45am
|
|
Actinogen CEO presents to Spark Plus Biotech conference
|
24 February 2023 at 10:30am
|
|
Appendix 4D & Half-Year Financial Statements
|
22 February 2023 at 2:20pm
|
|
Actinogen appoints Dr Dana Hilt as Chief Medical Officer
|
1 February 2023 at 9:30am
|
|
Quarterly Activity Report & Appendix 4C
|
30 January 2023 at 9:50am
|
|
ACW CEO presentation Sachs Neuroscience and JPM week
|
9 January 2023 at 9:10am
|
|
Letter to Shareholders - CEO 2022 Review & Outlook
|
22 December 2022 at 2:40pm
|
|
FDA agrees to six-month Phase 2b Alzheimers Disease Trial
|
22 December 2022 at 12:25pm
|
|
Cleansing Notice
|
9 December 2022 at 11:10am
|
|
Application for quotation of securities - ACW
|
9 December 2022 at 11:10am
|
|
First patient treated in XanaCIDD Phase 2 Depression Trial
|
8 December 2022 at 1:50pm
|
|
Actinogen poster presentation at CTAD conference 2022
|
5 December 2022 at 8:45am
|
|
Constitution
|
16 November 2022 at 1:40pm
|
|
Results of AGM
|
16 November 2022 at 1:30pm
|
|
Actinogen AGM Chair address & CEO presentation
|
16 November 2022 at 10:15am
|
|
Appendix 3Y - Dr George Morstyn
|
11 November 2022 at 2:55pm
|
|
Cleansing Notice
|
11 November 2022 at 2:10pm
|
|
Application for quotation of securities - ACW
|
11 November 2022 at 2:10pm
|
|
ACW CEO presentation to Bell Potter Healthcare Conference
|
9 November 2022 at 11:45am
|
|
Appendix 3Y - Dr Steven Gourlay
|
4 November 2022 at 9:55am
|
|
Actinogen CEO presentation to Spark Plus Healthcare Day
|
3 November 2022 at 12:30pm
|
|
Quarterly Activity Report & Appendix 4C
|
28 October 2022 at 9:25am
|
|
Actinogen CEO presentation to ShareCafe investor webinar
|
21 October 2022 at 9:35am
|
|
R&D tax incentive rebate received
|
20 October 2022 at 1:40pm
|
|
Annual Report to Shareholders
|
14 October 2022 at 12:15pm
|
|
Letter to Shareholders, Notice of AGM & Proxy Form
|
14 October 2022 at 12:15pm
|
|
ACW clinical biomarker study webcast presentation
|
10 October 2022 at 10:10am
|
|
ACW announces positive Alzheimers Disease clinical results
|
10 October 2022 at 9:45am
|
|
Trading Halt
|
6 October 2022 at 10:00am
|
|
Date of AGM and Closing Date for Director Nominations
|
28 September 2022 at 8:45am
|
|
Actinogen AD Biomarkers Context & History Presentation
|
13 September 2022 at 6:40pm
|
|
Appendix 4G
|
25 August 2022 at 6:50pm
|
|
Corporate Governance Statement
|
25 August 2022 at 6:50pm
|
|
Actinogen FY22 Results - Accelerating Clinical Development
|
25 August 2022 at 6:50pm
|
|
ACW Appendix 4E and 2022 Annual Report
|
25 August 2022 at 6:50pm
|
|
Actinogen Spark Plus non deal roadshow investor presentation
|
11 August 2022 at 9:25am
|
|
Actinogen Clinical Trials Science Forum presentation slides
|
3 August 2022 at 9:55am
|
|
ACW CEO presentation to Spark Plus Aust Equities Day
|
28 July 2022 at 10:05am
|
|
Quarterly Activity Report & Appendix 4C
|
28 July 2022 at 9:45am
|
|
ACW CEO to present at Spark Plus Aust Equities Day
|
25 July 2022 at 3:25pm
|
|
Actinogen Clinical Trials Science Forum Save the Date
|
21 July 2022 at 9:55am
|
|
Application for quotation of securities - ACW
|
15 July 2022 at 12:55pm
|
|
Actinogen Alzheimer Disease Biomarker Study Timing & Design
|
13 July 2022 at 10:30am
|
Actinogen Medical